Skip to main content




Malaysia to buy more Pfizer-BioNTech doses, eyes China's single-dose vaccine

Malaysia to buy more Pfizer-BioNTech doses, eyes China's single-dose vaccine

FILE PHOTO: Workers transfer a container carrying the first batch of Pfizer-BioNTech COVID-19 vaccines at the MASkargo Complex in Sepang, Malaysia February 21, 2021. Malaysia Information Department/Famer Roheni/Handout via REUTERS

KUALA LUMPUR: Malaysia will buy additional doses of Pfizer-BioNTech's COVID-19 vaccine, bringing the total secured to 32 million, enough to cover half of its population, the country's science minister Khairy Jamaluddin said on Monday (Mar 8). 

The Southeast Asian country last month embarked on a nationwide vaccination programme, targeting to inoculate 80 per cent of its 32 million people by February 2022.

"All of the Pfizer vaccines secured so far are expected to be delivered by this year," Khairy said at a virtual news conference.

IN FOCUS: After grappling with COVID-19 for more than a year, is Malaysia finally turning the corner? 

READ: Malaysia detects two cases of new COVID-19 variant

Malaysia is also considering dropping negotiations to procure a single-dose vaccine from US pharmaceutical firm Johnson & Johnson, in favour of a deal with Chinese company CanSino Biologics, which also requires only one dose, Khairy said.

"This is a better option for us compared to Johnson & Johnson, where supplies are expected to arrive only in the fourth quarter of the year," he added.

The government said last month it had secured 66.7 million vaccine doses, more than enough to cover its population.

In addition to the deal with Pfizer-BioNTech, Malaysia has also reached a supply agreement with Britain's AstraZeneca, Russia's Gamaleya Research Institute, as well as China's Sinovac Biotech and CanSino.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak:

Source: Reuters


Also worth reading